Glenmark Pharmaceuticals Limited, a research‐led global integrated pharmaceutical company, Q4 FY 2020‐21, consolidated revenue was at Rs. 2,859.9 crores as against Rs. 2,767.5 crores recording an increase of 3.3%. 

Consolidated net profit was at Rs. 233.9 crores for the quarter ended March 31, 2021 as compared to Rs. 220.3 crores in the previous corresponding quarter, registering an increase of 6.2%. 

For the year ended March 31, 2021, Glenmark’s consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period. Consolidated Net Profit grew by 25% to Rs. 970.1 crores for the year ended March 31, 2021, as against Rs. 776 crores in the previous year. 

Earnings Per Share (EPS) is at Rs. 34.38 as compared to Rs. 27.5 in the previous year. 

“We delivered consistent performance during the year despite operational challenges due to the COVID19 pandemic. We led from the front in India's fight against the pandemic at its very onset, with our leading brand FabiFlu,” said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Ltd. 

“We have in place strategic levers to grow our businesses sustainably, with focus on strengthening our balance sheet,” added Saldanha.